StreetInsider.com News Articles

Form 6-K Evaxion A/S For: Aug 20

Thu, 20 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260820/26952924.html

Form 6-K Evaxion A/S For: Aug 20

Thu, 20 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260820/26952924.html

Evaxion posts $3.7M Q2 loss, advances cancer vaccine pipeline

Thu, 20 Aug 2026 07:31:13 -0400

Evaxion A/S (NASDAQ: EVAX), a Copenhagen-based clinical-stage vaccine company, reported a net loss of $3.7 million for the second quarter ended June 30, 2026, compared to a net loss of $4.8 million in the same period a year earlier, according to a company press release.

Research and development expenses were $2.3 million for the quarter, a slight increase from $2.2 million in the second quarter of 2025. General and administrative expenses fell to $1.5 million from $2.2 million in the year-ago period, primarily due to lower capital market costs. Cash and cash equivalents stood at $14.0 million as of June 30,

Evaxion announces business update and second quarter 2026 financial results

Thu, 20 Aug 2026 07:30:00 -0400

COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces second quarter 2026 financial results.

Business highlights (since last quarterly update)
Evaxion is making steady progress towards completing its strategic milestones for 2026. Highlights include:

Announcing the upcoming presentation of three-year clinical data for personalized cancer vaccine candidate EVX-01 at the ESMO Congress 2026
Presentation of new data for EVX-04, an off-the-shelf cancer vaccine for acute myeloid leukemia (AML)
Expansion and refocusing of our R&D pipeline with EVX-05, a

Evaxion announces business update and second quarter 2026 financial results

Thu, 20 Aug 2026 07:30:00 -0400

Business highlights (since last quarterly update)
Evaxion is making steady progress towards completing its strategic milestones for 2026. Highlights include:

Announcing the upcoming presentation of three-year clinical data for personalized cancer vaccine candidate EVX-01 at the ESMO Congress 2026
Presentation of new data for EVX-04, an off-the-shelf cancer vaccine for acute myeloid leukemia (AML)
Expansion and refocusing of our R&D pipeline with EVX-05, a

Form 6-K Evaxion A/S For: Jun 30

Thu, 20 Aug 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260820/26952883.html

Form 6-K Evaxion A/S For: Jun 30

Thu, 20 Aug 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260820/26952883.html

Form 6-K Evaxion A/S For: Aug 17

Mon, 17 Aug 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260817/26935162.html

Form 6-K Evaxion A/S For: Aug 17

Mon, 17 Aug 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260817/26935162.html

Evaxion adds brain cancer vaccine program, drops EVX-03

Mon, 17 Aug 2026 08:02:52 -0400

Evaxion A/S (NASDAQ: EVAX) announced the addition of EVX-05, a therapeutic vaccine candidate targeting glioblastoma, to its research and development pipeline, according to a company statement dated August 17, 2026.

EVX-05 is designed as an off-the-shelf vaccine targeting endogenous retrovirus-derived antigens shared among glioblastoma patients. The targets were identified using Evaxion's AI-Immunology platform. Evaxion is collaborating with Duke University School of Medicine on the program, with Professor Mustafa Khasraw and his team expected to conduct initial clinical testing.

Glioblastoma has an incidence rate of 3.19 per 100,000 persons in the United States, according to the National Institutes of Health. The New England

Evaxion adds brain cancer vaccine program, drops EVX-03

Mon, 17 Aug 2026 08:02:52 -0400

Glioblastoma has an incidence rate of 3.19 per 100,000 persons in the United States, according to the National Institutes of Health. The New England

Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program